Though the diagnostic accuracy of CSF 14-3-3β was moderate compared to CSF p-tau and CSF t-tau in distinguishing CN Aβ− from Alzheimer’s disease Aβ+ individuals, baseline CSF 14-3-3β levels were associated with progressive decline of cognitive function over time. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.